Cargando…
LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer
Lung cancer is the most common cancer globally and is associated with high morbidity and mortality. Gefitinib has been widely used for treating advanced non-small-cell lung cancer (NSCLC). However, acquired resistance usually develops, although we still know little about the mechanism underlying thi...
Autores principales: | Xu, Tianwei, Yan, Shuai, Wang, Mengwei, Jiang, Lihua, Ma, Pei, Lu, Binbin, Chen, Qinnan, Wei, Chenchen, Wang, Zhaoxia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235350/ https://www.ncbi.nlm.nih.gov/pubmed/32477939 http://dx.doi.org/10.3389/fonc.2020.00656 |
Ejemplares similares
-
LncRNA UCA1 in anti-cancer drug resistance
por: Wang, Haohao, et al.
Publicado: (2017) -
The prognostic value and mechanisms of lncRNA UCA1 in human cancer
por: Yao, Fei, et al.
Publicado: (2019) -
lncRNA GAS8-AS1 downregulates lncRNA UCA1 to inhibit osteosarcoma cell migration and invasion
por: Zha, Zhuqing, et al.
Publicado: (2020) -
lncRNA-UCA1 in the diagnosis of bladder cancer: A meta-analysis
por: Ding, Zhenshan, et al.
Publicado: (2021) -
LncRNA MSTO2P promotes colorectal cancer progression through epigenetically silencing CDKN1A mediated by EZH2
por: Guo, Mengjun, et al.
Publicado: (2022)